Eyevensys wins approval to start clinical development of EyeCET platform

Private biotech Eyevensys said today that it won approval from the UK Medicines and Healthcare Products Regulatory Agency to advance its EyeCET platform into clinical development.

The company’s EyeCET platform uses an electro-transfection injection system to deliver non-viral plasmids that encode for disease-specific therapeutic proteins in the ciliary muscle of the eye. Eyevensys’ lead product delivers a plasmid that encodes for the production of a protein to treat non-infectious uveitis.

Get the full story at our sister site, Drug Delivery Business News.

The post Eyevensys wins approval to start clinical development of EyeCET platform appeared first on MassDevice.

from MassDevice http://ift.tt/2pHZ4Cq